Nicotinamide-GMP-Like-Niacinamide-GMP-Like-生命科学试剂-MCE

Hotline:400-820-3792Inhibitors•ScreeningLibraries•Proteinswww.MedChemENicotinamide(GMPLike)Cat.No.:HY-B0150GLCASNo.:98-92-0Synonyms:Niacinamide(GMPLike);Nicotinicacidamide(GMPLike)分⼦式:C₆H₆N₂O分⼦量:122.12作⽤靶点:EndogenousMetabolite;Sirtuin;HBV作⽤通路:MetabolicEnzyme/Protease;CellCycle/DNADamage;Epigenetics;Anti-infection储存⽅式:PleasestoretheproductundertherecommendedconditionsintheCertificateofAnalysis.BIOLOGICALACTIVITY⽣物活性Nicotinamide(GMPLike)(Niacinamide(GMPLike))GMPLike级别的Nicotinamide(HY-B0150)。GMPLike级别的⼩分⼦可⽤做细胞疗法中的辅助试剂。Nicotinamide维⽣素B3或烟酸的⼀种形式。Nicotinamide可抑制SIRT2的活性，其IC50值为2μM。Nicotinamide也抑制SIRT1。Nicotinamide增加细胞内NAD+、ATP、ROS⽔平。Nicotinamide抑制肿瘤⽣长并提⾼⽣存率。NicotinamideHydrochloride还具有抗-HBV活性。体外研究Nicotinamide(GMPLike)(0-50mM,24/48h)reducescellnumberinatime-dependentanddose-dependentmannerinA375andSK-MEL-28cells[1].Nicotinamide(GMPLike)(10-50mM,24h)makesA375cellsundergoaccumulationinG1phase,reductioninSphase,andincreaseinthesub-G1(apoptosis)phase[1].Nicotinamide(GMPLike)(1-50mM,6h)increasesNAD+,ATPandROSlevelsinA375andSK-MEL-28cells[1].Nicotinamide(GMPLike)(0.01-20mM,1h)inhibitspurifiedSIRT2enzymaticactivityinvitrowithanEC50of2μM[1].Nicotinamide(GMPLike)(0-64mM)inhibitsHBVreplicationinHepAD38andHepG2.2.15cells[3].Nicotinamide(GMPLike)(10mM,onday13)promotespancreaticcelldifferentiationfromhumanembryonicstemcells(hESCs)throughCK1andROCKinhibition[4].CellViabilityAssay[1]CellLine:A375,SK-MEL-28,mouseB16-F10cell1/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemEConcentration:0,1,20,50mMIncubationTime:24h,48hResult:Reducedcellnumberinadose-dependentmannerwithastronginhibitoryeffectat20mMandanalmostcompleteeffectat50mM.CellCycleAnalysis[1]CellLine:A375,SK-MEL-28Concentration:10,20,50mMIncubationTime:24hResult:ArrestedA375cellsinG1phase.体内研究Nicotinamide(GMPLike)(Intraperitonealinjection,1500and1800mg/Kg,5daysperweek)inhibitstumorgrowthinmurinemetastaticmelanomamodel[1].Nicotinamide(GMPLike)(Intraperitonealinjection,1800mg/Kg,onceaday,murinemetastaticmelanomamodel)affectsIFN-γ(akeymediatorofcell-mediatedanti-tumorimmunity),increasestheplasmalevelsofEotaxinandIL-5,reducestheplasmalevelsofIL-3,IL-12,RANTESandIL-10[1].Nicotinamide(GMPLike)(veininjection,0-200mg/kg,5days)inhibitsHBVreplicationinHBV-transgenicmice[3].AnimalModel:C57BL/6mice(subcutaneousinjectedwithB16-F10cells)[1]Dosage:1000,1500,1800mg/Kg.Administration:Intraperitonealinjection,5daysperweek(followedby2-dayrest)oronceaday.Result:Inhibitedtumorgrowthat1500and1800mg/Kg,andhadnoeffectonthebodyweight.IncreasedthefrequencyofIFN-γproducingcellsandmodulatedtheproteinlevelsofcytokinesandchemokinesintheplasmaoftumor-bearingmice.AnimalModel:HBV-transgenicmice[3]Dosage:0-200mg/kgAdministration:Veininjection,5daysResult:ReducedserumHBVDNA.户使⽤本产品发表的科研⽂献2/3MasterofBioactiveMolecules—您⾝边的抑制剂⼤师www.MedChemE•CancerCell.2024Oct14;42(10):1729-1746.e8.•NatPhotonics.2025Jul10.•NatGenet.2023Dec;55(12):2175-2188.•CellStemCell.2022Sep1;29(9):1366-1381.e9.•MolCell.2025Apr3;85(7):1349-1365.e10.Seemorecustomervalidationsonwww.MedChemEREFERENCES[1].FrancescaScatozza,etal.Nicotinamideinhibitsmelanomainvitroandinvivo.JExpClinCancerRes.2020Oct7;39(1):211.[2].HwangES,etal.NicotinamideisaninhibitorofSIRT1invitro,butcanbeastimulatorincells.CellMolLifeSci.2017Sep;74(18):3347-3362.[3].LiWY,etal.TheSIRT1inhibitor,nicotinamide,inhibitshepatitisBvirusreplicationinvitroandinvivo.ArchVirol.2016Mar;161(3):621-30.[4].ZhangY,etal.NicotinamidepromotespancreaticdifferentiationthroughthedualinhibitionofCK1andROCKkinasesinhumanembryonicstemcells.StemCellResTher.2021Jun25;12(1):362.McePdf